252 related articles for article (PubMed ID: 25728039)
1. Characterization of CD22 expression in acute lymphoblastic leukemia.
Shah NN; Stevenson MS; Yuan CM; Richards K; Delbrook C; Kreitman RJ; Pastan I; Wayne AS
Pediatr Blood Cancer; 2015 Jun; 62(6):964-9. PubMed ID: 25728039
[TBL] [Abstract][Full Text] [Related]
2. Therapy-related myeloid neoplasm in an 18-year-old boy with B-lymphoblastic leukemia.
Qing X; Panosyan E; Yue C; Ji P; Gotesman M; French S; Cai J
Exp Mol Pathol; 2017 Dec; 103(3):263-266. PubMed ID: 29155023
[TBL] [Abstract][Full Text] [Related]
3. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.
Raetz EA; Cairo MS; Borowitz MJ; Blaney SM; Krailo MD; Leil TA; Reid JM; Goldenberg DM; Wegener WA; Carroll WL; Adamson PC;
J Clin Oncol; 2008 Aug; 26(22):3756-62. PubMed ID: 18669463
[TBL] [Abstract][Full Text] [Related]
4. [Clinical and molecular biologic characteristics of 36 cases of leukemia with 11q23/mll].
Zhao J; Yin YM; Zhao YL; Sun Y; Wang JB; Zhong J; Zhang X; Fei XH; Shan FX; Liu HX; Wang T; Wang H; Tong CR; Wu T; Lu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1381-5. PubMed ID: 21176334
[TBL] [Abstract][Full Text] [Related]
5. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia.
Pui CH; Behm FG; Downing JR; Hancock ML; Shurtleff SA; Ribeiro RC; Head DR; Mahmoud HH; Sandlund JT; Furman WL
J Clin Oncol; 1994 May; 12(5):909-15. PubMed ID: 8164041
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
Wayne AS; Kreitman RJ; Findley HW; Lew G; Delbrook C; Steinberg SM; Stetler-Stevenson M; Fitzgerald DJ; Pastan I
Clin Cancer Res; 2010 Mar; 16(6):1894-903. PubMed ID: 20215554
[TBL] [Abstract][Full Text] [Related]
7. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
[TBL] [Abstract][Full Text] [Related]
8. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
9. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
Dahl J; Marx K; Jabbour E
Expert Rev Hematol; 2016; 9(4):329-34. PubMed ID: 26783163
[TBL] [Abstract][Full Text] [Related]
10. (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.
Chevallier P; Eugene T; Robillard N; Isnard F; Nicolini F; Escoffre-Barbe M; Huguet F; Hunault M; Marcais A; Gaschet J; Cherel M; Guillaume T; Delaunay J; Peterlin P; Eveillard M; Thomas X; Ifrah N; Lapusan S; Bodet-Milin C; Barbet J; Faivre-Chauvet A; Ferrer L; Bene MC; Le Houerou C; Goldenberg DM; Wegener WA; Kraeber-Bodéré F
Lancet Haematol; 2015 Mar; 2(3):e108-17. PubMed ID: 26687796
[TBL] [Abstract][Full Text] [Related]
11. Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage.
Palle J; Frost BM; Forestier E; Gustafsson G; Nygren P; Hellebostad M; Jonsson OG; Kanerva J; Schmiegelow K; Larsson R; Lönnerholm G;
Br J Haematol; 2005 Apr; 129(2):189-98. PubMed ID: 15813846
[TBL] [Abstract][Full Text] [Related]
12. Lineage switch in childhood acute leukemia: an unusual event with poor outcome.
Rossi JG; Bernasconi AR; Alonso CN; Rubio PL; Gallego MS; Carrara CA; Guitter MR; Eberle SE; Cocce M; Zubizarreta PA; Felice MS
Am J Hematol; 2012 Sep; 87(9):890-7. PubMed ID: 22685031
[TBL] [Abstract][Full Text] [Related]
13. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Fry TJ; Shah NN; Orentas RJ; Stetler-Stevenson M; Yuan CM; Ramakrishna S; Wolters P; Martin S; Delbrook C; Yates B; Shalabi H; Fountaine TJ; Shern JF; Majzner RG; Stroncek DF; Sabatino M; Feng Y; Dimitrov DS; Zhang L; Nguyen S; Qin H; Dropulic B; Lee DW; Mackall CL
Nat Med; 2018 Jan; 24(1):20-28. PubMed ID: 29155426
[TBL] [Abstract][Full Text] [Related]
14. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement.
Jansen MW; Corral L; van der Velden VH; Panzer-Grümayer R; Schrappe M; Schrauder A; Marschalek R; Meyer C; den Boer ML; Hop WJ; Valsecchi MG; Basso G; Biondi A; Pieters R; van Dongen JJ
Leukemia; 2007 Apr; 21(4):633-41. PubMed ID: 17268512
[TBL] [Abstract][Full Text] [Related]
15. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.
Raponi S; De Propris MS; Intoppa S; Milani ML; Vitale A; Elia L; Perbellini O; Pizzolo G; Foá R; Guarini A
Leuk Lymphoma; 2011 Jun; 52(6):1098-107. PubMed ID: 21348573
[TBL] [Abstract][Full Text] [Related]
16. Variables affecting the quantitation of CD22 in neoplastic B cells.
Jasper GA; Arun I; Venzon D; Kreitman RJ; Wayne AS; Yuan CM; Marti GE; Stetler-Stevenson M
Cytometry B Clin Cytom; 2011 Mar; 80(2):83-90. PubMed ID: 20872890
[TBL] [Abstract][Full Text] [Related]
17. Screening of Variations in CD22 Gene in Children with B-Precursor Acute Lymphoblastic Leukemia.
Aslar Oner D; Akin DF; Sipahi K; Mumcuoglu M; Ezer U; Kürekci AE; Akar N
Genet Test Mol Biomarkers; 2016 Sep; 20(9):552-5. PubMed ID: 27486888
[TBL] [Abstract][Full Text] [Related]
18. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.
de Vries JF; Zwaan CM; De Bie M; Voerman JS; den Boer ML; van Dongen JJ; van der Velden VH
Leukemia; 2012 Feb; 26(2):255-64. PubMed ID: 21869836
[TBL] [Abstract][Full Text] [Related]
19. Targeting CD22 in B-cell malignancies: current status and clinical outlook.
Sullivan-Chang L; O'Donnell RT; Tuscano JM
BioDrugs; 2013 Aug; 27(4):293-304. PubMed ID: 23696252
[TBL] [Abstract][Full Text] [Related]
20. A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer.
Jahn L; Hagedoorn RS; van der Steen DM; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH
Oncotarget; 2016 Nov; 7(44):71536-71547. PubMed ID: 27689397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
